ISI Papers With Our Products
Title: Co-electrospraying technology as a novel approach for dry powder inhalation formulation of montelukast and budesonide for pulmonary co-delivery
Journal: International Journal of Pharmaceutics
Author: 1. Shadi Yaqoubi, 2. Khosro Adibkia, 3. Ali Nokhodchi, 4. Shahram Emami, 5. Ali Akbar Alizadeh, 6. Hamed Hamishehkar, 7. Mohammad Barzegar-Jalali
Year: 2020
Address: 1. Faculty of Pharmacy and Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2. Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
3. Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex, UK
4. Department of Pharmaceutics, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran
5. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
7. Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences,
Tabriz, Iran
Abstract: In the current study electrospraying methodology was used for particle engineering of montelukast and budesonide to prepare a combined inhalable dry powder formulation applicable as a smart regimen in asthma treatment. For this, electrospraying was carried out using different solvents and drug concentrations. No carrier was added for the formulation of montelukastbudesonide combination as montelukast played the role of both active ingredient and carrier. Scanning electron microscopy, particle size analysis, gas chromatography, powder X-ray diffraction, Fourier transform infrared spectroscopy, and differential scanning calorimetry were used to evaluate the physicochemical properties of the produced drug particles. In vitro drug
deposition pattern was assessed using next generation impactor, and the dissolution profile of the selected formulations was characterized via modified diffusion franz cell method. The FPF value for the co-electrosprayed carrier free formulation of montelukast-budesonide was 38% with a significantly enhanced dissolution rate for budesonide compared to the budesonide alone
formulations. The pharmacological effects of hypothesized combined formulation was assessed by measuring its power to inhibit the production of reactive oxygen species in human normal
lung cells. The results showed that the combination of montelukast and budesonide can exert a synergistic effect. The findings in the current study emphasize that using montelukast as a carrier for budesonide not only has greatly improved the aerosolization behavior and dissolution rate of
budesonide but also has resulted in synergistic pharmacological effects, indicating the suitability of this combination as an anti-asthmatic therapeutic.
Keywords: dry powder inhalation, pulmonary drug delivery, montelukast, budesonide,
combination therapy, electrospray, particle engineering
Application: Drug Delivery
Product Model 1: High Voltage Power Supply (HV35POV)
Product Model 2: Syringe Pump (SP1000HOM)
URL: #https://pubmed.ncbi.nlm.nih.gov/33059013/#